Business
AGM Statement and Notice of Investor Evening
AGM Statement and Notice of Investor Evening.
About this update from Iconic Labs Plc
[{"type":"text","content":"\n \nRNS Number : 7942I WideCells Group PLC 22 June 2017 \n\n22 June 2017\nWideCells Group PLC ('WideCells Group' or 'the Group')\nAGM Statement and Notice of Investor Evening\n \nWideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, will hold its Annual General Meeting ('AGM') today. After the AGM João Andrade, Chief Executive Officer, will provide a corporate update, highlighting the progress made since listing in all three divisions. A new corporate presentation, which will be used by Mr Andrade to present with, will be available to view on the Company's website later today: www.widecellsgroup.com. Furthermore, the Company will be hosting a private investor evening on Wednesday 12 July 2017, further details of which are set out below.\n \nAt the AGM Mr Andrade will make the following statement:\n \n\"It is nearly a year since we first floated WideCells Group on the London Stock Exchange in July 2016. Since this time, we have made astronomical progress in building a revenue generative end-to-end stem cell support services company. Testament to this is the recognition we received from DISRUPT 100, an annual index celebrating the businesses with the most potential to influence, change or create new global markets, where WideCells Group was ranked as the 21st most disruptive company globally. This award is a great honour and I believe gives an indication of the huge impact our business is set to make on the medical world. \n \n\"The business currently has three primary divisions, being CellPlan Limited ('CellPlan'), WideCells Group Science ('WideCells') and WideAcademy, with four potential revenue streams. With revenues now being received and set to increase from WideCells, from both storage and research, and the launch of our core stem cell insurance product in June 2017 creating a third, we have reached an inflection point as we enter a new and significant period of growth. \n \n\"Taking a look first at CellPlan, we founded this division having recognised a significant flaw in the stem cell industry; whilst more than 3 million people around the globe have paid c.£2,000 to store stem cells, many do not realise that the cost of treatment can be up to...